FDA gene therapy oversight

CRISPR gene editing trends in US clinical trials are entering a more disciplined phase defined by regulatory clarity, platform diversification, and maturing capital allocation. What began as proof-of-concept studies in rare hematologic disorders has expanded into oncology, in vivo editing, and next-generation delivery systems. For biotechnology executives and investors, the trajectory of CRISPR programs now … Read more